Insight Molecular Diagnostics Publishes Groundbreaking Data on GraftAssure Transplant Rejection Assay
Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) published new data in the American Journal of Transplantation showing its flagship assay, GraftAssure, is statistically superior for detecting kidney transplant rejection. The study supports potential FDA approval and broader adoption of the test kit, though market skepticism remains due to competition and regulatory hurdles.
Tickers: $IMDX
Topics: diagnostics FDA_approval micro-cap_stocks transplant_rejection_monitoring